Evaluation of 167 Gene Expression Classifier (GEC) and ThyroSeq v2 Diagnostic Accuracy in the Preoperative Assessment of Indeterminate Thyroid Nodules: Bivariate/HROC Meta-analysis
Open Access
- 27 December 2018
- journal article
- research article
- Published by Springer Nature in Endocrine Pathology
- Vol. 30 (1) , 8-15
Abstract
The objective of this meta-analysis was to evaluate the performance of the Gene Expression Classifier (GEC) and ThyroSeq v2 (ThyroSeq) in the preoperative diagnosis of thyroid nodules with indeterminate fine-needle aspiration biopsy results. We searched literature databases from January 2001 to April 2018. The bivariate model analysis was performed to estimate pooled sensitivity, specificity, positive likelihood ratio (LR+), negative likelihood ratio (LR−), positive predictive value (PPV), and negative predictive value (NPV). Pooled data from 1086 nodules with histopathologic confirmation from 16 GEC studies enabled calculation of diagnostic parameters (95% confidence interval): sensitivity 98% (96–99%), specificity 12% (8–20%), PPV 45% (37–53%), and NPV 91% (85–96%). Pooled data from five ThyroSeq studies assessing 459 nodules showed sensitivity of 84% (74–91%), specificity 78% (50–92%), PPV 58% (31–81%), and NPV 93% (89–97%). When both tools were compared, GEC had a significantly higher sensitivity (p = 0.003), while ThyroSeq had a significantly higher specificity (p < 0.001) and accuracy (p = 0.015). Pooled LR+ was higher for ThyroSeq: 3.79 (1.40–10.27) vs. 1.12 (1.05–1.20). Pooled LR− was higher for GEC, 0.20 (0.10–0.39) vs. 0.13 (0.05–0.31). The bivariate summary estimates of sensitivity and specificity for GEC and ThyroSeq and their pooled accuracy showed a superiority of the ThyroSeq test. The GEC with a high sensitivity and NPV may be helpful in ruling out malignancy in cases of indeterminate thyroid nodule cytology. ThyroSeq has a significantly higher specificity and accuracy with an acceptable sensitivity so that it has the potential for use as an all-round test of malignancy of thyroid nodules.Keywords
Funding Information
- PRELUDIUM Grant of Polish National Center for Science (2015/19/N/NZ5/02257)
This publication has 31 references indexed in Scilit:
- Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next‐generation sequencing assayCancer, 2014
- Implications of a suspicious afirma test result in thyroid fine‐needle aspiration cytology: An institutional experienceCancer Cytopathology, 2014
- Malignancy Rate in Thyroid Nodules Classified as Bethesda Category III (AUS/FLUS)Thyroid®, 2014
- Surgical Utility of Afirma: Effects of High Cancer Prevalence and Oncocytic Cell Types in Patients with Indeterminate Thyroid CytologyEndocrine Practice, 2014
- Multicenter Clinical Experience With the Afirma Gene Expression ClassifierThe Journal of Clinical Endocrinology & Metabolism, 2014
- Bivariate meta-analysis of predictive values of diagnostic tests can be an alternative to bivariate meta-analysis of sensitivity and specificityJournal of Clinical Epidemiology, 2012
- Preoperative Diagnosis of Benign Thyroid Nodules with Indeterminate CytologyNew England Journal of Medicine, 2012
- The Bethesda System for Reporting Thyroid Cytopathology: A Meta-AnalysisActa Cytologica, 2012
- Impact of Mutational Testing on the Diagnosis and Management of Patients with Cytologically Indeterminate Thyroid Nodules: A Prospective Analysis of 1056 FNA SamplesThe Journal of Clinical Endocrinology & Metabolism, 2011
- Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviewsJournal of Clinical Epidemiology, 2005